中文
About Us
Corporate Overview
Management Team
Board of Directors
Contact Us
Our Focus
Metabolic Diseases
Immune Diseases
Exploratory Indications
Pipeline
Pipeline
Clinical Trials
Partnership
Investors
Financials & Filing
News
Careers
Investors
Financials & Filing
2025
2024
2023
2022
2021
2020
2019
2018
2025
2024
2023
2022
2021
2020
2019
2018
Next Day Disclosure Returns - Share Buyback
2024-12-31
Next Day Disclosure Returns - Share Buyback
2024-12-30
Next Day Disclosure Returns - Share Buyback
2024-12-27
Next Day Disclosure Returns - Share Buyback
2024-12-20
Next Day Disclosure Returns - Share Buyback
2024-12-19
Voluntary Announcement - Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model
2024-12-18
Next Day Disclosure Returns - Share Buyback
2024-12-13
Next Day Disclosure Returns - Share Buyback
2024-12-12
Next Day Disclosure Returns - Share Buyback
2024-12-11
Next Day Disclosure Returns - Share Buyback
2024-12-10
1
2
3
4
»
浙公网安备 33010802003344号
浙ICP备11050387号-1